# Tiotropium Bromide in Cystic Fibrosis

> **NCT01179347** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 464 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** tiotropium Respimat® inhaler
- **DRUG:** Placebo Respimat® inhaler

## Key facts

- **NCT ID:** NCT01179347
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 464 (ACTUAL)
- **Last updated:** 2013-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01179347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01179347, "Tiotropium Bromide in Cystic Fibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01179347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*